Safety of Prasugrel in Indian patients - multicentric registry of 1000 cases.

Background: Clopidogrel has been the only available antiplatelet drug used along with aspirin in patients of ACS. In recent years 2 new antiplatelet drugs (Prasugrel and Ticagrelor) have become available. Prasugrel in the dose of 10 mg OD has been found to be more efficacious but with increased risk of major bleeding.

Images in cardiology: dual LAD circulation. a rare coronary anomaly.

Aim: We report a case of type IV dual Left anterior descending (LAD) coronary artery detected incidentally in a female who presented with atypical chest pain.

Method: She underwent coronary angiography which showed dual LAD--one from the LMCA and another from right coronary sinus.

Results: Coronary angiography helped in the diagnosis of the rare coronary anomaly.

Intra cardiac mass--a diagnostic and therapeutic dilemma.

Aim: We report an unusual case of previously healthy post partum woman who had presented with congestive cardiac failure. She had no significant past history.

Method: She underwent cardiac evaluation.

Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study.

The results of primary coronary stenting for acute myocardial infarction (AMI) have been reported to improve significantly with the concomitant administration of platelet glycoprotein IIb/IIIa inhibitor abciximab. There are, however, no data available with the use of eptifibatide, a more cost-effective, small-molecule GP IIb/IIIa blocker with a shorter half-life. In a prospective multicenter feasibility and efficacy study, we assigned 55 consecutive patients with AMI being taken up for primary stenting to receive eptifibatide just before the procedure (two boluses of 180 microg/kg 10 min apart and a 24-hr infusion of 2 microg/kg/min).